Clinical Trial Update: Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating low-dose recombinant human IL-2 for relapsing polychondritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Polychondritis

Drugs mentioned

• recombinant human IL-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Relapsing Polychondritis | Phase 2 | Status: COMPLETED